GILEAD AND GALAPAGOS REPORT UPDATED SAFETY INFORMATION FOR FILGOTINIB IN RHEUMATOID ARTHRITIS (RA) - NASDAQ.com - Nasdaq

GILEAD AND GALAPAGOS REPORT UPDATED SAFETY INFORMATION FOR FILGOTINIB IN RHEUMATOID ARTHRITIS (RA) - NASDAQ.com  Nasdaq

Pooled Interim Phase 3 FINCH Program Data up to 24 Weeks and Phase 2 b DARWIN 3 Long-Term Data Add to Evidence Supporting Filgotinib Safety.